Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Natalizumab effects on immune cell responses in multiple sclerosis.

Annals of neurology - 1 May 2006

Niino Masaaki, Bodner Caroline, Simard Marie-Lune, Alatab Sudabeh, Gano Dawn, Kim Ho Jin, Trigueiro Manuela, Racicot Denise, Guérette Christine, Antel Jack P, Fournier Alyson, Grand'Maison Francois, Bar-Or Amit

Abstract excerpt

OBJECTIVE: Our objective was to study in vivo biological effects of natalizumab on immune cell phenotype and function in multiple sclerosis (MS) patients. METHODS: Blood was obtained before and after serial monthly natalizumab infusions to track functional expression of VLA-4 and migratory capaci...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Cell Separation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunity, Cellular

Share to In Vitro Techniques

Share to Infusions, Intravenous

Share to Monocytes

Share to Multiple Sclerosis, Relapsing-Remitting

Share to Stimulation, Chemical

Source

Identifiers

PMID: 16634035
DOI: 10.1002/ana.20859

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-16634035-2026-09-04.1. Manifest publication-graph-cohort-2026-09-04.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Natalizumab effects on immune cell responses in multiple sclerosis.PMID 16634035Read ↗

Immune surveillance in multiple sclerosis patients treated with natalizumab.Semantic proximity Read ↗

Fingolimod alters intrathecal B cell maturation in multiple sclerosis patientsSemantic proximity Read ↗

Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activitySemantic proximity Read ↗

Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.Semantic proximity Read ↗

Characterization of the impact of daclizumab beta on circulating natural killer cells by mass cytometrySemantic proximity Read ↗

Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab.Semantic proximity Read ↗

Safety and Immune Effects of Blocking CD40 Ligand in Multiple SclerosisSemantic proximity Read ↗

A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation.Semantic proximity Read ↗

Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.Semantic proximity Read ↗

Different patterns of activation markers expression and CD4+ T-cell responses to ex vivo stimulation in patients with clinically quiescent multiple sclerosis (MS)Semantic proximity Read ↗

Differential effects of fingolimod on B-cell populations in multiple sclerosis.Semantic proximity Read ↗

Vitamin D differentially modulates effector and regulatory T-cell migration across the blood-brain barrierSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.